ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Pharmacologic Class Indexing
- Class set ID
- 82c6c9b8-3cdd-453e-92a4-2ae12919ce94
- Version
- 2
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use KOVALTRY safely and effectively. See full prescribing information for KOVALTRY. KOVALTRY [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection – Reconstitution with Vial Adapter Initial U.S. Approval: 2016 | Bayer HealthCare LLC | 20260302 | 18 |
| These highlights do not include all the information needed to use ADYNOVATE ® safely and effectively. See full prescribing information for ADYNOVATE. ADYNOVATE, (Antihemophilic Factor, Recombinant, PEGylated) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 2015 | Takeda Pharmaceuticals Amercia, Inc. | BAXALTA US INC. | Siegfried Hameln GmbH | 20251016 | 23 |
| RECOMBINATE ® [Antihemophilic Factor (Recombinant)] | Takeda Pharmaceuticals America, Inc. | Baxalta US Inc. | 20250403 | 21 |
| These highlights do not include all the information needed to use ADVATE ® safely and effectively. See full prescribing information for ADVATE. ADVATE [antihemophilic factor (recombinant)] lyophilized powder for reconstitution, for intravenous injection Initial U.S. Approval: 2003 | Takeda Pharmaceuticals America, Inc. | Baxalta US INC | Baxalta Manufacturing Sarl | Takeda Manufacturing Austria AG | Takeda Manufacturing Singapore Pte. Ltd. | Siegfried Hameln GmbH | 20250403 | 13 |
| These highlights do not include all the information needed to use ESPEROCT ® safely and effectively. See full prescribing information for ESPEROCT. ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2019 | Novo Nordisk | Vetter Pharma Fertigung GmbH & Co. KG | 20240701 | 7 |
| These highlights do not include all the information needed to use NOVOEIGHT safely and effectively. See full prescribing information for NOVOEIGHT. NOVOEIGHT (antihemophilic factor, recombinant) lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2013 | Novo Nordisk | 20200731 | 12 |
| RECOMBINATE [Antihemophilic Factor (Recombinant)] | Baxter Healthcare Corporation | 20100526 | 7 |